- $34.33m
- $38.71m
- $13.90m
- 52
- 40
- 29
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.38 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.44 | ||
| EV to EBITDA | 132.6 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.76% | ||
| Return on Equity | -5.69% | ||
| Operating Margin | -0.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.36 | 9.66 | 11.18 | 12.27 | 13.9 | n/a | n/a | 9.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Radnostix, Inc., formerly International Isotopes Inc., manufactures a wide range of radioisotope-focused products. The Company manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. The Company provides contract manufacturing of various drug products as well as radioisotope active pharmaceutical ingredient (API) supply for third party theranostics clients. The Company manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and single photon emission computed tomography (SPECT)/positron emission tomography (PET) imaging systems as well as industrial calibration standards under its RadQual brand. The Company also manufactures Cobalt-60 sealed source products.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- November 1st, 1995
- Public Since
- August 14th, 1997
- No. of Shareholders
- 458
- No. of Employees
- 41
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 528,209,538
- Address
- 4137 Commerce Cir, IDAHO FALLS, 83401-1205
- Web
- https://intisoid.com/
- Phone
- +1 2085245300
- Contact
- David Drewitz
- Auditors
- Haynie & Co.
Upcoming Events for INIS
Q1 2026 RADNOSTIX, INC. Earnings Release
Similar to INIS
Acusphere
Pink Sheets on Nasdaq
Adaptimmune Therapeutics
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
Aleafia Health
Pink Sheets on Nasdaq
FAQ
What is the RADNOSTIX,. share price?
As of Today at 20:21 UTC, shares in RADNOSTIX,. are trading at $0.07. This share price information is delayed by 15 minutes.
How has the RADNOSTIX,. share price performed this year?
Shares in RADNOSTIX,. last closed at $0.07 and the price had moved by +74.5% over the past 365 days. In terms of relative price strength the RADNOSTIX,. share price has outperformed the S&P500 Index by +41.39% over the past year.
What are the analyst and broker recommendations for RADNOSTIX,.?
There is no consensus recommendation for this security.
Find out moreWhat is the RADNOSTIX,. dividend yield?
RADNOSTIX,. does not currently pay a dividend.
Does RADNOSTIX,. pay a dividend?
RADNOSTIX,. does not currently pay a dividend.
When does RADNOSTIX,. next pay dividends?
RADNOSTIX,. does not currently pay a dividend.
How do I buy RADNOSTIX,. shares?
To buy shares in RADNOSTIX,. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of RADNOSTIX,.?
As of the previous close price of $0.07, shares in RADNOSTIX,. had a market capitalisation of $34.33m.
Where are RADNOSTIX,. shares listed?
Here are the trading details for RADNOSTIX,.:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: INIS
What kind of share is RADNOSTIX,.?
Based on an overall assessment of its quality, value and momentum RADNOSTIX,. is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a RADNOSTIX,. share price forecast for 2026?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the RADNOSTIX,. share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RADNOSTIX,.. Over the past six months, its share price has underperformed the S&P500 Index by -30.52%.
As of the last closing price of $0.07, shares in RADNOSTIX,. were trading -1.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the RADNOSTIX,. PE Ratio?
The RADNOSTIX,. PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of RADNOSTIX,.?
RADNOSTIX,.'s management team is headed by:
- Christopher Grosso - NEC
- Steve Laflin - CEO
- Matthew Cox - CFO
- Robert Atcher - IND